Loading
CytoMed Therapeutics Ltd Stock: price and insider trades · United States
US·Mcap US$10.4M
1 insider bought €263k of shares over the last 90 days, the latest filed 24 Jul 2026.
CytoMed Therapeutics Ltd: what insiders have been doing
CytoMed Therapeutics Ltd is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, 4 filings were filed, from 2 insiders.
Only purchases show up on the open market, 3 purchases in all worth €373k, filed by 1 insider. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The largest single trade was a purchase of €132k by Choo Chee Kong, published on 24 July 2026, equal to 1.4% of the market capitalisation. Those buying include 1 senior executive.
The last purchase on record was published on 24 July 2026, which is 86 days ago. Filings reach the SEC (Form 4) feed a median of 10 days after the trade. US insiders must file a Form 4 within two business days of a trade.
Compared with its exchange (5,813 companies, median 19 filings), a count of 4 filings is below the norm. Looking back to 2026, when coverage begins, insiders filed 3 purchases and no sales.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
4
Thresholds
n/a
Buy Volume
€372,761
3 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleChee Kong Choo3 buys
Since the insiders bought
- +11.1%Entry US$0.90 · Close at T+30 US$1.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,498 of 24,161 companies
27.0
score / 100
Value6
Quality49
FCF yld-42%
Earn yld-38%
EV/EBITDA·
ROE-56%
Gross mgn79%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.87
Analyst consensus
1 analysts1.00/5
US$4.16Target US$4.16(+378%)US$4.16
Income statement
RevenueUS$324.4k
Gross profitUS$256.4k79% margin
EBITDA-US$3.6M-1102% margin
Net income-US$4M-1227.1% margin
Valuation
P/Book2.7x
Beta0.07
Balance sheet & cash
Market capUS$10.4M
Total debtUS$482.6k
Free Cash Flow-US$4.4M
Debt / Equity8%
Profitability & ownership
ROE-56.2%
ROA-32.5%
% insiders70.5%
% institutions0.1%
Last declaration on 11 August 2026
Declarations4 total
100,000 shares@ US$1.501.39% mcap35.3% of flowORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITEDSEC:0001493152-26-034516:0
Canonical exit: 12 Oct 2026 (T+90)
100,000 shares@ US$1.501.39% mcap35.2% of flowORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITEDSEC:0001493152-26-034516:1
Canonical exit: 18 Oct 2026 (T+90)
112,000 shares@ US$1.149829.5% of flowOrdinary Shares, no par value per shareSEC:0001493152-26-028589:0
Canonical exit: 11 Aug 2026 (T+90)
4 of 4 declarations
About CytoMed Therapeutics Ltd
CytoMed Therapeutics Ltd is a company focused on developing innovative therapies based on cell medicine. It is listed on the NASDAQ.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
